BPC-157
A synthetic pentadecapeptide widely studied in animal models of soft-tissue and gastrointestinal repair.
Clinical review required · Pricing after approval
Products
Explore the therapies available through MECCA. Product interest does not guarantee approval. Every patient request is reviewed before pricing, payment and pharmacy fulfillment are released.
Most people know what they want to change before they know which therapy to ask about. Choose a goal to see the options commonly discussed for it.
A synthetic pentadecapeptide widely studied in animal models of soft-tissue and gastrointestinal repair.
Clinical review required · Pricing after approval
A long-acting amylin analogue studied for appetite regulation and weight management.
Clinical review required · Pricing after approval
A commonly prescribed secretagogue pairing, co-formulated in a single vial.
Clinical review required · Pricing after approval
A copper-binding tripeptide that has been studied in dermatologic settings.
Clinical review required · Pricing after approval
A selective secretagogue, studied for its limited effect on cortisol or prolactin.
Clinical review required · Pricing after approval
A mitochondrial-derived peptide studied in metabolic regulation and exercise physiology.
Clinical review required · Pricing after approval
A cellular cofactor central to energy metabolism, delivered by infusion or injection.
Clinical review required · Pricing after approval
A melanocortin agonist that acts centrally on sexual desire rather than on blood flow.
Clinical review required · Pricing after approval
An investigational triple agonist acting at GLP-1, GIP and glucagon receptors.
Clinical review required · Pricing after approval
A GLP-1 receptor agonist studied for weight and glycaemic management.
Clinical review required · Pricing after approval
The only GHRH analogue with an approved indication for visceral fat reduction.
Clinical review required · Pricing after approval
An immune peptide studied in this category, with approved use in several countries.
Clinical review required · Pricing after approval
A dual GIP and GLP-1 receptor agonist with the largest weight effect of the approved incretins.
Clinical review required · Pricing after approval
Nothing here is purchasable. Everything below still requires clinical review.
57 products
A small molecule studied for its effect on fat-cell metabolism and cellular energy handling.
Clinical review required · Pricing after approval
A modified fragment of human growth hormone studied for effects on fat metabolism.
Clinical review required · Pricing after approval
An erythropoietin-derived peptide studied in small-fibre neuropathy and tissue repair.
Clinical review required · Pricing after approval
Sterile diluent used to reconstitute lyophilised therapies before administration.
Clinical review required · Pricing after approval
A synthetic pentadecapeptide widely studied in animal models of soft-tissue and gastrointestinal repair.
Clinical review required · Pricing after approval
A co-formulated recovery blend that reduces the injection burden of two peptides.
Clinical review required · Pricing after approval
A long-acting amylin analogue studied for appetite regulation and weight management.
Clinical review required · Pricing after approval
A growth-hormone-releasing hormone analogue used in secretagogue protocols.
Clinical review required · Pricing after approval
A commonly prescribed secretagogue pairing, co-formulated in a single vial.
Clinical review required · Pricing after approval
A longer-acting form of CJC-1295 with a drug-affinity complex extending its half-life.
Clinical review required · Pricing after approval
Delta sleep-inducing peptide, studied for its effect on slow-wave sleep and stress response.
Clinical review required · Pricing after approval
A co-formulated sleep and anxiolytic-signalling blend.
Clinical review required · Pricing after approval
A tetrapeptide studied in Russian gerontology literature for pineal and telomere signalling.
Clinical review required · Pricing after approval
A senolytic peptide studied in preclinical models of cellular senescence.
Clinical review required · Pricing after approval
A copper-binding tripeptide that has been studied in dermatologic settings.
Clinical review required · Pricing after approval
A growth-hormone-releasing peptide acting on the ghrelin receptor.
Clinical review required · Pricing after approval
An earlier-generation secretagogue notable for a pronounced appetite effect.
Clinical review required · Pricing after approval
A co-formulated aesthetic and repair blend combining GHK-Cu with two recovery peptides.
Clinical review required · Pricing after approval
A synthetic form of gonadotropin-releasing hormone used to support endogenous signalling.
Clinical review required · Pricing after approval
A potent secretagogue with additional cardiac signalling studied in preclinical work.
Clinical review required · Pricing after approval
A long-acting analogue of insulin-like growth factor 1.
Clinical review required · Pricing after approval
A selective secretagogue, studied for its limited effect on cortisol or prolactin.
Clinical review required · Pricing after approval
A gentler secretagogue pairing for patients new to this category.
Clinical review required · Pricing after approval
A neuropeptide upstream of GnRH, studied in reproductive and sexual-response signalling.
Clinical review required · Pricing after approval
A four-component repair blend adding KPV's anti-inflammatory signalling to the GLOW base.
Clinical review required · Pricing after approval
A tripeptide fragment of alpha-MSH studied for anti-inflammatory signalling.
Clinical review required · Pricing after approval
A human antimicrobial peptide studied in innate immune defence and wound repair.
Clinical review required · Pricing after approval
A dual GLP-1 and glucagon receptor agonist studied for weight and metabolic outcomes.
Clinical review required · Pricing after approval
An alpha-MSH analogue studied for photoprotective pigmentation.
Clinical review required · Pricing after approval
A non-selective melanocortin agonist with both pigmentary and sexual-response effects.
Clinical review required · Pricing after approval
A mitochondrial-derived peptide studied in metabolic regulation and exercise physiology.
Clinical review required · Pricing after approval
A cellular cofactor central to energy metabolism, delivered by infusion or injection.
Clinical review required · Pricing after approval
A neuropeptide studied in social bonding, mood and intimate response.
Clinical review required · Pricing after approval
A pegylated mechano-growth-factor variant studied in muscle repair.
Clinical review required · Pricing after approval
A short peptide from the bioregulator literature, studied for neuroprotective signalling.
Clinical review required · Pricing after approval
A peptide bioregulator studied in prostate tissue function.
Clinical review required · Pricing after approval
A melanocortin agonist that acts centrally on sexual desire rather than on blood flow.
Clinical review required · Pricing after approval
A co-formulated intimate-health blend combining central, endocrine and neuropeptide signalling.
Clinical review required · Pricing after approval
A co-formulated intimate-health blend pairing desire, bonding and endocrine signalling.
Clinical review required · Pricing after approval
An investigational triple agonist acting at GLP-1, GIP and glucagon receptors.
Clinical review required · Pricing after approval
A synthetic analogue of tuftsin studied for anxiolytic signalling without sedation.
Clinical review required · Pricing after approval
A co-formulated nootropic pairing of two neuropeptides.
Clinical review required · Pricing after approval
A GLP-1 receptor agonist studied for weight and glycaemic management.
Clinical review required · Pricing after approval
An ACTH-fragment analogue studied for attention, mood and neurotrophic signalling.
Clinical review required · Pricing after approval
A short-acting GHRH analogue and a conservative option in this category.
Clinical review required · Pricing after approval
A topical octapeptide studied for the appearance of expression lines.
Clinical review required · Pricing after approval
A mitochondria-targeted peptide studied in cardiolipin stabilisation and cellular energetics.
Clinical review required · Pricing after approval
An investigational dual GLP-1 and glucagon receptor agonist.
Clinical review required · Pricing after approval
A synthetic fragment of thymosin beta-4 studied in systemic tissue repair.
Clinical review required · Pricing after approval
The only GHRH analogue with an approved indication for visceral fat reduction.
Clinical review required · Pricing after approval
A co-formulated pairing combining a well-studied GHRH analogue with a selective secretagogue.
Clinical review required · Pricing after approval
A thymic peptide complex studied for immune regulation in older adults.
Clinical review required · Pricing after approval
An immune peptide studied in this category, with approved use in several countries.
Clinical review required · Pricing after approval
A co-formulated thymic blend pairing two immune-regulatory peptides.
Clinical review required · Pricing after approval
A three-component immune and anti-inflammatory blend.
Clinical review required · Pricing after approval
A dual GIP and GLP-1 receptor agonist with the largest weight effect of the approved incretins.
Clinical review required · Pricing after approval
A neuropeptide studied in inflammatory regulation and mucosal immunity.
Clinical review required · Pricing after approval
Nothing is reserved, charged or shipped until a licensed clinician has decided it is appropriate for you.
Review products by goal, category or treatment type.
Select the products you want to discuss.
A licensed clinician reviews your information and determines what is appropriate.
Approved patients receive pricing and payment instructions. The pharmacy ships directly to the patient.
MECCA does not recommend therapy from a product list alone. Treatment decisions are based on goals, health history, current medications, relevant testing and clinical judgment.
Learn Our ApproachYes. Your request opens a consultation rather than a prescription. A clinician reviews what you have asked about, then decides whether care with MECCA is appropriate and what that care should be.
No. Pricing is released with your approved plan, once a clinician has decided the therapy is appropriate for you. We do not publish patient pricing on this page or anywhere else on the site.
No. A request is a starting point for a clinical conversation. Your clinician may approve it, adjust it, or decline it — and will explain the reasoning either way.
Often, yes. What you receive reflects your goals, health history, current medications and relevant testing — not the list you arrived with.
A licensed pharmacy partner prepares and dispenses approved therapy and ships directly to the patient, or prepares it for clinic pickup where cold-chain handling requires it.
Compounded preparations are not FDA-approved as finished products. They are prepared by state-licensed compounding pharmacies for an individual patient on a prescription. We tell you when a therapy is compounded and what that means.
Yes. Add as many as you would like to discuss. Your clinician reviews them together, because interactions and sequencing matter more than any single item.
Choose "I want MECCA to recommend the appropriate options" in the treatment request. Describe your goals and history, and let the clinical judgment come first.
We'll talk through your history and goals and tell you honestly whether MECCA is the right fit. No pressure, no packages, no obligation.